This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
milla1cf Fri, 02/23/2024 - 11:54 February 23, 2024 — Cleerly , the company creating a new standard of care to aid in the diagnosis of heartdisease, announced that its recently U.S. Prior studies have demonstrated the independent and incremental benefit of Cleerly ISCHEMIA applied to CCTA beyond traditional assessment.
milla1cf Thu, 03/28/2024 - 07:00 March 28, 2024 — Cleerly , the company on a mission to create a new standard of care to aid in the diagnosis of heartdisease, shared findings from a study published online in the Journal of the American College of Cardiology: CardiovascularImaging on March 13, 2024. 2024.01.007.
Cleerly, a digital healthcare company focused on heartdisease, has announced continued strong scientific evidence supporting the clinical utility of its products, detailing a study published online on Jan. 25, 2024 in the European Heart Journal CardiovascularImaging. In Press European Heart Journal CV Imag 2024.This
Kawasaki disease (KD), an acute self-limited febrile illness that primarily affects children <5 years old, is the leading cause of acquired heartdisease in developed countries, with the potential of leading to coronary artery dilation and coronary artery aneurysms in 25% of untreated patients.
Within the complex umbrella of cardiovasculardisease, CAD is a type of heartdisease that develops when the coronary arteries narrow and the heart cannot deliver enough oxygen-rich blood to the heart.
Circulation: CardiovascularImaging, Ahead of Print. BACKGROUND:Stress perfusion cardiovascular magnetic resonance can be performed without rest perfusion for the quantification of ischemia burden. The absence of ischemia by either analysis strategy conferred a favorable long-term prognosis.
American Society of Echocardiography clinical recommendations for multimodality cardiovascularimaging of patients with pericardial disease: endorsed by the Society for Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed Tomography. J Am Soc Echocardiogr. 2013 Sep;26(9):965-1012.e15.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content